The prognostic value of platelet count in patients with hepatocellular carcinoma: A systematic review and meta-analysis

Medicine (United States)

Volumn 94, Issue 37, 2015, Pages

  Pang, Qing ^a   Qu, Kai ^a   Zhang, Jing Yao ^a   Song, Si Dong ^a   Liu, Su Shun ^a   Tai, Ming Hui ^a   Liu, Hao Chen ^a   Liu, Chang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; BLOOD; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPLICATION; LIVER NEOPLASMS; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HUMANS; LIVER NEOPLASMS; OBSERVATIONAL STUDIES AS TOPIC; PLATELET COUNT; THROMBOCYTOPENIA;

EID: 84941957057     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001431     Document Type: Article

References (74)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58:273-277.
3. Chong RJ, Abdullah MS, Hossain MM, et al. Rising incidence of primary liver cancer in Brunei Darussalam. Asian Pac J Cancer Prev. 2013;14:3473-3477.
4. Buonaguro L, Petrizzo A, Tagliamonte M, et al. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013;59:897-903.
5. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297.
6. Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer <2 cm: results from two Western centers. Hepatology. 2013;57:1426-1435.
7. Mao YM, Luo ZY, Li B, et al. Prospective study on the survival of HCC patients treated with transcatheter arterial lipiodol chemoembolization. Asian Pac J Cancer Prev. 2012;13:1039-1042.
8. Choi HJ, Kim DG, Na GH, et al. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol. 2013;19:4737-4744.
9. Worns MA, Bosslet T, Victor A, et al. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol. 2012;47:718-728.
10. Kondo R, Yano H, Nakashima O, et al. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C. J Gastroenterol. 2013;48:526-534.
11. Udell JA, Wang CS, Tinmouth J, et al. Does this patient with liver disease have cirrhosis? JAMA. 2012;307:832-842.
12. Lannerstedt H, Konopski Z, Sandvik L, et al. Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver. Scand J Gastroenterol. 2013;48:93-100.
13. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology. 2007;46:912-921.
14. Ucar F, Sezer S, Ginis Z, et al. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;25:1076-1081.
15. Akuta N, Suzuki F, Seko Y, et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;56:2134-2141.
16. Wang JH, Chang KC, Kee KM, et al. Hepatocellular carcinoma surveillance at 4-vs.12-month intervals for patients with chronic viral hepatitis: A randomized study in community. Am J Gastroenterol. 2013;108:416-424.
17. El-Serag HB, Kanwal F, Davila JA, et al. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146:1249-1255.e1.
18. Nathan H, Herlong HF, Gurakar A, et al. Clinical decision-making by gastroenterologists and hepatologists for patients with early hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1844-1851.
19. Pang Q, Zhang JY, Song SD, et al. Thrombocytopenia as an inexpensive, valuable predictor for survival in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2014;49:1507-1508.
20. Zheng Z, Zhou L, Gao S, et al. Prognostic role of C-reactive protein in hepatocellular carcinoma: A systematic review and meta-analysis. Int J Med Sci. 2013;10:653-664.
21. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
22. Chung IK, Park MJ, Kwon KT, et al. The factors related to the prognosis of solitary hepatocellular carcinoma after radiofrequency ablation. Korean J Hepatol. 2005;11:371-380.
23. Amano H, Tashiro H, Oshita A, et al. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg. 2011;15:1173-1181.
24. Arimura E, Kotoh K, Nakamuta M, et al. Local recurrence is an important prognostic factor of hepatocellular carcinoma. World J Gastroenterol. 2005;11:5601-5606.
25. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U. S.-Canadian multicenter study. J Hepatol. 2007;47:527-537.
26. Camma C, Di Marco V, Orlando A, et al. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): A prospective study. J Hepatol. 2005;42:535-540.
27. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856-1864.
28. Hiroishi K, Eguchi J, Baba T, et al. Strong CD8 (+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2010;45:451-458.
29. Ikeda M, Maeda S, Shibata J, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24-31.
30. Kang CM, Choi GH, Kim DH, et al. Revisiting the role of nonanatomic resection of small (< or=4cm) and single hepatocellular carcinoma in patients with well-preserved liver function. J Surg Res. 2010;160:81-89.
31. Kao WY, Chiou YY, Hung HH, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol. 2012;46:62-70.
32. Kim SJ, Choi IK, Park KH, et al. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol. 2004;34:184-190.
33. Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gammacarboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009;115:571-580.
34. Kobayashi T, Itamoto T, Tashiro H, et al. Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. J Hepatobiliary Pancreat Sci. 2011;18:689-699.
35. Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virusrelated hepatocellular carcinoma. Dig Dis Sci. 2012;57:1092-1101.
36. Niizeki T, Sumie S, Torimura T, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012;47:686-695.
37. Nishikawa H, Osaki Y, Iguchi E, et al. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol. 2013;48:951-965.
38. Nouso K, Ito Y, Kuwaki K, et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer. 2008;98:1161-1165.
39. Ochiai T, Ogino S, Ishimoto T, et al. Prognostic impact of hepatectomy for patients with non-hepatitis B, non-hepatitis C hepatocellular carcinoma. Anticancer Res. 2014;34:4399-4410.
40. Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with hepatocellular carcinoma: A new prognostic indicator after hepatectomy. Cancer. 1998;83:58-63.
41. Tseng PL, Wang JH, Tung HD, et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426-1434.
42. Wong KM, Yeh ML, Chuang SC, et al. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol. 2013;32:253-257.
43. Wu WC, Chiou YY, Hung HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46:789-795.
44. Wu ZF, Xu Z, Li WS, et al. Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res. 2015;193:153-160.
45. Xie H, Wang H, An W, et al. The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One. 2014;9:e89081.
46. Guo X, Chen M, Ding L, et al. Application of Cox model in coagulation function in patients with primary liver cancer. Hepatogastroenterology. 2011;58:326-330.
47. Ishizuka M, Kubota K, Kita J, et al. Duration of hepatic vascular inflow clamping and survival after liver resection for hepatocellular carcinoma. Br J Surg. 2011;98:1284-1290.
48. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50:1475-1483.
49. Li X, Chen ZH, Ma XK, et al. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2014;35:11057-11063.
50. Seo JY, Kim W, Kwon JH, et al. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. Liver Int. 2013;33:884-893.
51. Tateishi R, Shiina S, Akahane M, et al. Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. PLoS One. 2013;8:e59040.
52. Tsuchiya M, Kono H, Matsuda M, et al. Protective effect of Juzentaiho- to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer. 2008;123:2503-2511.
53. Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130:2747-2760.
54. Akuta N, Suzuki F, Kobayashi M, et al. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014;86:131-138.
55. Nozaki R, Murata S, Nowatari T, et al. Effects of thrombopoietin on growth of hepatocellular carcinoma: is thrombopoietin therapy for liver disease safe or not? Hepatol Res. 2013;43:610-620.
56. Yang T, Zhang J, Lu JH, et al. Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg. 2011;35:2073-2082.
57. Zhao WC, Zhang HB, Yang N, et al. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol. 2012;18:3272-3281.
58. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569-577quiz 578.
59. Minata M, Kudo M, Harada KH, et al. Expression of E-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection. Oncology. 2013;84(Suppl. 1):88-92.
60. Taketomi A, Kitagawa D, Itoh S, et al. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: An institute's experience with 625 patients. J Am Coll Surg. 2007;204:580-587.
61. Kaibori M, Kubo S, Nagano H, et al. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg. 2013;37:820-828.
62. Kao WY, Chiou YY, Hung HH, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol. 2012;67:429-436.
63. Kubo S, Tanaka H, Shuto T, et al. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res. 2004;30:221-225.
64. Hagiwara S, Kudo M, Kawasaki T, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214-1219.
65. Chen TM, Huang PT, Tsai MH, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2aribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669-675.
66. Kobeisy MA, Morsy KH, Galal M, et al. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol. 2012;13:49-53.
67. Shen SL, Fu SJ, Chen B, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21:3802-3809.
68. Hung HH, Su CW, Lai CR, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4:691-699.
69. Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107:988-993.
70. Pinato DJ, Stebbing J, Ishizuka M, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013-1020.
71. Cho SY, Lee A, Lee HJ, et al. Mean platelet volume in Korean patients with hepatic diseases. Platelets. 2012;23:648-649.
72. Cho SY, Yang JJ, You E, et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets. 2013;24:375-377.
73. Ceylan B, Mete B, Fincanci M, et al. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125:453-460.
74. Ceylan B, Fincanci M, Yardimci C, et al. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B? Eur J Gastroenterol Hepatol. 2013;25:606-612.